iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Last trade$0.7298
Day change+$0.0231 (+3.27%)
Day range$0.699 – $0.748
Volume372,478
Market cap$50M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$50.02M
Price / earnings
—
Price / book
0.64×
Price / sales
46.53×
EV / sales
4.27×
EV / EBITDA
-0.2×
Profitability
Earnings per share
-$0.37
Return on assets
-29.21%
Return on equity
-32.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.48×
Quick ratio
9.48×
Cash ratio
5.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.59M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IBIO, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$1.08M
$0
$0
$0
$100K
$200K
$0
$200K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.08M
$0
$0
$0
$100K
$200K
$0
$200K
Selling, general and administrative
$2.76M
-$2.18M
$5.11M
$0
$2.5M
$2.17M
$2.97M
$2.74M
Research and development
$6.65M
$8.56M
$3.25M
$0
$3.55M
$3.22M
$1.91M
$1.88M
Total operating expenses
$9.41M
$11.38M
$8.37M
$0
$6.05M
$5.4M
$4.88M
$4.62M
Operating income
-$8.34M
-$11.38M
-$8.37M
$0
-$5.95M
-$5.2M
-$4.88M
-$4.42M
Interest expense
$0
$46K
-$22K
$0
-$34K
-$44K
-$54K
-$57K
Income before taxes
-$7.55M
-$10.58M
-$7.76M
$0
-$5.72M
-$5.16M
-$4.86M
-$4.36M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.55M
-$10.58M
-$7.76M
$0
-$5.72M
-$5.16M
-$4.86M
-$4.36M
Net income attributable to common shareholders
-$7.55M
-$10.58M
-$7.76M
$0
-$5.72M
-$5.16M
-$4.86M
-$4.36M
EBITDA
-$8.19M
-$6.23M
-$8.21M
$0
-$5.82M
-$5.07M
-$4.75M
-$4.29M
Basic earnings per share
-$0.05
-$0.04
-$0.06
$0.00
-$0.11
-$0.36
-$0.49
-$0.48
Diluted earnings per share
-$0.05
-$0.04
-$0.06
$0.00
-$0.11
-$0.36
-$0.49
-$0.48
Recent news
Company coverage with links to the original publishers.
iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.
iBio, Inc. (NASDAQ: IBIO) announced a private placement financing of approximately $26 million led by Frazier Life Sciences. The company will use proceeds to advance preclinical cardiometabolic programs including IBIO-610 and IBIO-600, extending cash runway into calendar 2028. The offering is expected to close on January 13, 2026.
iBio, an AI-driven biotechnology company, will present at the Guggenheim Healthcare Innovation Conference in Boston, discussing its development of precision antibody therapies for obesity and cardiometabolic diseases.
iBio and AstralBio have developed a novel amylin receptor agonist antibody that significantly reduced acute food intake in a mouse model of obesity, comparable to a leading amylin peptide agonist. The findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases.
iBio has in-licensed a potentially best-in-class long-acting anti-myostatin antibody from AstralBio and is launching a new program featuring a myostatin + activin A bispecific antibody designed to promote weight loss, prevent muscle loss and weight regain.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.